Citigroup’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Citigroup’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,100	Closed	-$122K	–	7838
2020 Q3	$122K	Hold	1,100	–	–	﹤0.01%	4964
2020 Q2	$112K	Sell	1,100 -300	-21%	-$32.1K	﹤0.01%	5493
2020 Q1	$151K	Buy	1,400 +100	+8%	+$11.5K	﹤0.01%	4978
2019 Q4	$151K	Sell	1,300 -22,400	-95%	-$2.59M	﹤0.01%	5414
2019 Q3	$2.71M	Sell	23,700 -1,500	-6%	-$149K	﹤0.01%	2536
2019 Q2	$2.4M	Buy	25,200 +4,500	+22%	+$424K	﹤0.01%	2649
2019 Q1	$1.89M	Buy	20,700 +6,900	+50%	+$565K	﹤0.01%	2710
2018 Q4	$1.05M	Buy	13,800 +2,600	+23%	+$191K	﹤0.01%	3339
2018 Q3	$896K	Buy	+11,200	New	+$1.04M	﹤0.01%	3618

Citigroup's CBPO Position: Q2 2021 in Review

Citigroup sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 95,847 shares — an estimated $11.3M sold.

Citigroup first reported a position in CBPO in Q2 2013 and held it in 30 quarters. The position peaked at $11.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

Citigroup reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
Citigroup sold 95,847 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $11.3M.
Citigroup first reported a position in China Biologic Products Holdings, Inc. in Q2 2013 and held it in 30 quarters.
Citigroup's China Biologic Products Holdings, Inc. position peaked at $11.3M in Q1 2021.
0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.